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Abstract
Background: Recent studies have demonstrated that axillary lymph node dissection (ALND) does not affect patient survival,
even in those with one or two positive sentinel lymph nodes (SLNs). On the other hand, patients with 3 or more metastatic
lymph nodes are eligible for chemotherapy. Therefore, it is crucial to identify a priori patients at risk of having a high
number of metastatic axillary lymph nodes for their surgical and/or clinical management. Ultrasound (US) guided Fine-
Needle Aspiration (FNA) has been proven to be a useful and highly specific method for detecting metastatic axillary lymph
nodes. However, only one recent study has evaluated the efficiency of this method in identifying patients with high
metastatic nodal involvement. Our aim was to validate US-guided FNA as a reliable method to discriminate a priori patients
with .3 metastatic lymph nodes.
Methods: A retrospective series of 1287 breast cancer patients who underwent a simultaneous preoperative breast and
axillary US to stage their axilla was collected. A total of 365 patients, with either positive SLNs (278) or positive axillary lymph
nodes detected via US-guided FNA (87), underwent ALND. In these two subgroups, we compared the number of metastatic
lymph nodes in the axilla.
Results: The number of metastatic axillary lymph nodes in patients who underwent US-guided FNA was significantly higher
(63% had .3 metastatic lymph nodes) than that in patients with SLNs positive for micro- or macrometastases (3% and 27%,
respectively) (P,0.001, x2 = 117.897).
Conclusions: Preoperative axillary US-guided FNA could act as a reliable tool in identifying breast cancer patients with
extensive nodal involvement.
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Introduction
For years, the sentinel lymph node (SLN) biopsy has been
considered the standard technique in staging axillary lymph nodes
in breast cancer patients [1]. Traditional protocols indicate that
breast cancer patients with positive SLNs require a thorough
examination of their axillary lymph nodes, while patients with
negative SLNs can skip axillary lymph node dissection (ALND).
However, the optimal management of the axilla is a matter of
discussion again, following the results of a trial by Giuliano et al.
[2]. This study did not detect any differences in survival among
patients with T1–T2 breast cancer, with one or two positive SLNs,
treated with breast conservation and systemic therapy alone or
with ALND. Other studies [3,4] have reported that only 30% of
patients with positive SLNs showed involvement of other axillary
lymph nodes and that axillary recurrence in patients not treated
with ALND was uncommon.
On the other hand, the status of axillary lymph nodes remains
an important prognostic index of overall and disease-free survival,
and the number of metastatic nodes is considered by oncologists
when deciding whether to administer chemotherapy, mainly in
patients with estrogen receptor (ER)-positive cancer [5]. In
particular, the last Consensus Meeting in St. Gallen recommended
the use of chemotherapy in patients with more than 3 metastatic
axillary lymph nodes [6].
Therefore, for both the surgical and oncological management of
patients, it is critical to identify a priori those eligible for ALND.
To this end, several nomograms have been proposed [7,8].
Axillary ultrasonography (US) guided Fine-Needle Aspiration
cytology (FNA) of suspicious lymph nodes is recognised as an
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optimal preoperative procedure for identifying patients eligible for
ALND [9–12]. In 2003, we published one of the first studies
demonstrating that US-guided FNA of suspicious axillary lymph
nodes could reliably be introduced as a preoperative procedure, to
address the surgical management of the axilla [9]. However, only
one recent study has evaluated the efficiency of US-guided FNA to
identify patients with high metastatic nodal involvement (.3
metastatic lymph nodes) [13]. Taking into account the results of
van Wely et al. [13], the present study aimed to validate US-
guided FNA as a reliable method that could be introduced into
routine practice to discriminate a priori patients with extensive
metastatic nodal involvement from those at low risk.
Methods
A retrospective case-series of 1287 invasive breast cancer
patients, operated between January 2004 and December 2012,
was collected (excluding patients on neoadjuvant therapy). This
cohort underwent simultaneous preoperative breast and axillary
US to stage the axilla. The criteria for defining a lymph node
suspected of containing metastases by US were (1) the loss of
lymph node shape; (2) a rounded appearance; (3) an increased
cortical thickening; (4) an echo-poor central hilus and (5) an
eccentricity of the nodal cortex.
In our Breast Unit, the protocol for the management of patients
with suspicious lymph nodes after a US examination (independent
of the number of suspect lymph nodes) is to perform a US-guided
FNA procedure, before proceeding to surgery. The axillary FNA is
performed on a single lymph node, using a 22-Gauge needle. In
case of multiple suspect lymph nodes, the easiest to target is
aspirated. The cytological material is smeared and immediately
fixed in methanol and stained with hematoxylin and eosin. The
pathologist, present on site, gives a diagnosis based on the presence
or absence of cancer cells in the smear. Hypocellular smears are
considered inadequate and additional FNAs are performed
depending on the feasibility of the aspiration procedure.
Patients with malignant axillary lymph nodes following US-
guided FNA bypass the SLN biopsy and undergo an ALND,
whereas those with normal axillary lymph nodes or benign/
inadequate FNA cytology receive a SLN biopsy followed by an
ALND if their SLN is positive (Figure 1). The SLN histopatho-
logical assessment is performed following the regional guidelines
[14] and the diagnosis is reported based on the TNM classification
[15].
If an ALND is performed, the number of excised lymph nodes
and the number of lymph nodes positive for metastases are
reported in the histopathological diagnosis.
For the purposes of the study, patient age, tumour histotype,
grade, size, vascular invasion, hormone receptor expression, Ki67
index value and HER2 status (Table 1) were recorded in a
dedicated database.
All clinical investigations have been conducted according to the
principles expressed in the Declaration of Helsinki.
The study was approved by the ethic institutional review board
for ‘‘Biobanking and use of human tissue for experimental studies’’
of the Pathology Services of the Azienda Ospedaliera Citta` della
Salute e della Scienza di Torino. Written informed consent was
obtained. Patient records were anonymized and de-identified prior
to analysis.
The data were analysed using the SPSS version 19 software
(SPSS, Inc., Chicago, IL. USA). Statistical significance was set at
P,0.05. Statistical analyses were performed using the chi-squared
test. A multivariate survival analysis was performed using the Cox
model. The concordance between an axillary US, an axillary FNA
and a SLN biopsy and the axillary lymph node status after an
ALND was estimated using the Cohen’s k statistic. The sensitivity,
specificity, positive predictive values (PPV) and negative predictive
values (NPV) of the combined axillary US-guided FNA and of US
alone were calculated.
Results
The clinical and pathological characteristics of 1287 patients
with breast cancer who underwent an axillary US examination are
described in Table 1.
In 154 (12%) patients, the US examination detected at least 1
suspicious lymph node, which was subjected to a US-guided FNA.
Of these cytological samples, 87 (57%) were diagnosed as
Figure 1. Axillary lymph nodes management in breast cancer patients US: ultrasound; FNA: fine needle aspiration; SLN: sentinel
lymph node; ITC: isolated tumour cells.
doi:10.1371/journal.pone.0106640.g001
Axillary Ultrasound Guided FNA in Breast Cancer Staging
PLOS ONE | www.plosone.org 2 September 2014 | Volume 9 | Issue 9 | e106640
Table 1. Clinical and histopathological characteristics of 1287 breast cancer patients who underwent axillary US examination.
Number of cases %
Age (years)
,40 47 3.6
40–49 185 14.3
50–69 753 58.5
$70 302 23.4
Histotype
Ductal 887 69
Lobular 249 19.3
Others 151 11.7
Grading
1 322 24.8
2 667 51.8
3 298 23
pT
1a 35 2.7
1b 236 18.3
1c 691 53.6
2 291 22.6
3 11 0.08
4 23 0.17
SLN
Negative+ITC 890 68.6
Micrometastasis 95 7.3
Macrometastasis 215 16.7
Not done 87 6.7
Vascular invasion
Absent 875 68
Present 412 32
Estrogen Receptor
0% 148 11.5
$1% 1139 88.5
Progesterone Receptor
0% 231 18
$1% 1056 82
Ki67
,14% 526 40.8
$14% 761 59.2
HER2
Negative 1115 86.6
Positive 172 13.4
Legend: SLN: Sentinel Lymph Node; ITC: Isolated Tumour Cells.
doi:10.1371/journal.pone.0106640.t001
Table 2. Metastatic involvement of the axilla in 154 breast cancer patients that underwent US-guided FNA.
US-guided FNA 154 (%) Metastatic involvement of the axilla Cohen’s k statistic
Yes (%) No (%)
Malignant 87 (56.5) 87 (100) 0 0.77
Benign/Inadequate 67 (43.5) 17 (25) 50 (75)
Legend: US: Ultrasonography; FNA: Fine-Needle Aspiration cytology; ALND: Axillary Lymph Node Dissection; SLN: Sentinel Lymph Node.
doi:10.1371/journal.pone.0106640.t002
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malignant (presence of cancer cells) and 59 (38%) as benign
(absence of cancer cells). Eight (5%) FNA specimens were
inadequate for diagnosis (Figure 1). ALND was performed in the
87 patients with malignant FNA, while the others underwent a
SLN biopsy. Altogether, the SLN surgical procedure was
performed in 1200 patients (67 diagnosed as benign or having
inadequate axillary lymph nodes following US-guided FNA and
1133 displaying no axillary involvement following a US)
(Figure 1). The mean number of SLNs excised was 1.2. The final
histopathological diagnoses of SLNs reported 215 (17.9%) patients
with macrometastases, 95 (7.9%) with micrometastases, 36 (3%)
with isolated tumour cells and 854 (71%) as negative. An ALND
was performed in 278 patients (205 positive for macrometastases
and 73 positive for micrometastases). The 10 patients with SLNs
positive for macrometastases rescued from the ALND were older
than 80 years of age (Figure 1).
Performance of combined axillary US-guided FNA and
SLN
All patients with positive axillary lymph nodes following US-
guided FNA showed metastatic disease in the ALND (Table 2).
The Cohen’s k statistic for the concordance between the
cytological results and histological axillary assessment following
ALND was 0.77 (Table 2).
With the aim to evaluate the performance of US alone in
detecting metastatic lymph nodes in the axilla, we focused on 67
cases with benign or inadequate US-guided FNA, which
underwent SLN biopsy. As shown in Table 3, we found 17 cases
identified as suspect by US and benign or inadequate by FNA, but
ultimately with metastatic SLN. None of them had an extracap-
sular extension. In particular, 8 macro- and 4 micrometastatic
SLNs were observed in 12 out of 59 patients with benign axillary
FNA and 3 macro- and 2 micrometastatic SLNs in 5 out of 8
patients with inadequate FNA samples. Thus, the US alone had a
sensitivity of 26.2%, a specificity of 94.3%, a PPV 67.5% of and a
NPV of 74.1%. On the contrary US-guided FNA reached 83.7%
sensitivity, 100% specificity, 100% PPV and 74.6% NPV.
In addition, we analysed the number of metastatic lymph nodes
detected after ALND, performed following the detection of either
a malignant US-guided FNA cytology or of a positive SLN. In the
first set of patients, 63% had .3 metastatic lymph nodes, whereas
only 20% of patients with metastatic SLN showed metastases in .
3 lymph nodes (Table 4). In particular, as shown in Figure 2, only
2.7% of the patients with SLN micrometastases and 26.8% with
SLN macrometastases had metastases in .3 lymph nodes (P,
0.001, x2 = 117.897). Moreover, of the 17 patients with negative or
inadequate FNA and positive SLNs, only 1 (5.8%) showed .3
metastatic lymph nodes; on the other hand 79.4% of the patients
with micrometastases and 52% of the patients with macrometas-
tases in the SLNs did not show any additional metastatic lymph
nodes after ALND (Figure 2).
In univariate analyses, malignant axillary lymph nodes following
US-guided FNA correlated with larger tumour size, higher tumour
grade, presence of vascular invasion, absence of progesterone
receptor expression, HER2 positivity, and Ki67.14% (Table 5).
However, in multivariate analyses only the pT-status maintained
its statistical significance (P= 0.01, OR 0.127, confidence interval
0.224–0.030).
Discussion
With the present study, we were able to validate the results
recently published by van Wely et al. [13] showing that the pre-
surgical US-guided FNA of axillary lymph nodes is a reliable
method with which to select patients at risk of high metastatic
involvement.
Several studies have been shown that the occurrence of
metastases in the lymph nodes of the axilla, even after one
positive SLN, could be a rare event [16,17], and nomograms have
been constructed to save patients from ALNDs, using parameters
mainly derived a posteriori, from the histopathological analysis of a
tumour specimen (size, grade, vascular invasion) and/or SLN
metastases [7,8,18–21]. However, Wo et al. [22] demonstrated
that even patients with small tumours (,0.5 cm in diameter) could
have several metastatic lymph nodes and that these patients have a
higher breast cancer-specific mortality than those with larger
Table 3. Relationship between US of the axilla with a suspect result, not confirmed by FNA and metastases in SLN.
US-Suspect/FNA benign/inadequate SLN positive SLN negative Total
FNA Benign 12 47 59
FNA Inadequate 5 3 8
Total 17 50 67
Legend: US: Ultrasonography; FNA: Fine-Needle Aspiration cytology; SLN: Sentinel Lymph Node.
doi:10.1371/journal.pone.0106640.t003
Table 4. Status of axillary lymph nodes in 365 breast cancer patients with positive US-guided FNA or positive SLN.
No metastases in the ALND Metastases in the ALND
1–3 LN* .3 LN*
Malignant US-guided FNA (87) 0 32 (36.7%) 55 (63.2%)
SLN Micro-and macroMTS (278) 165 (59.3%) 56 (20.2%) 57 (20.5%)
Legend: SLN: Sentinel Lymph Node; US: Ultrasonography; FNA: Fine-Needle Aspiration cytology. MTS: metastases; ALND: axillary lymph node dissection; LN: lymph
node.
*Including SLN.
doi:10.1371/journal.pone.0106640.t004
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Figure 2. Number of axillary metastatic lymph nodes in breast cancer patients with positive (micro- and macrometastases) sentinel
lymph nodes (SLNs) and in patients with positive ultrasound (US) guided fine needle aspiration cytology (FNA). The percentage of
cases with .3 axillary metastatic lymph nodes is higher in patients with positive US-guided FNA cytology than in patients with metastatic SLNs.
doi:10.1371/journal.pone.0106640.g002
Table 5. Clinical and histological characteristics of patients stratified on the basis of axillary US-guided FNA results.
Malignant US guided/FNA Benign US guided/FNA Inadequate US guided/FNA NO US guided/FNA P value (X2)
87 (%) 59 (%) 8 (%) 1133 (%)
Age (years)
,40 4 (4.5) 1 (1.6) 1 (12.5) 41 (3.6)
40–49 18 (20.6) 9 (15.2) 1 (12.5) 157 (13.8) Ns
50–69 45 (51.7) 33 (56) 4 (50) 671 (59.2)
$70 20 (23) 16 (27.1) 2 (25) 264 (23.3)
pT
pT1 27 (31) 45 (76.2) 5 (62.5) 885 (78.1)
pT2 44 (50.5) 12 (20.3) 3 (37.5) 232 (20.4) ,0.001
pT3 6 (6.8) 0 0 5 (0.4) (25.385)
pT4 10 (11.5) 2 (3.3) 0 11 (1)
Histotype
Ductal 65 (74.7) 41 (70) 8 (100) 773 (68.2)
Lobular 13 (15) 10 (17) 0 226 (20) Ns
Other 9 (10.3) 8 (13.5) 0 134 (11.8)
Grade
1 8 (9.1) 19 (32.2) 2 (25) 293 (26)
2 37 (42.5) 25 (42.3) 4 (50) 601 (53) ,0.001
3 42 (48.3) 15 (25.4) 2 (25) 239 (21) (36.326)
VI
Absent 21 (24) 43 (73) 4 (50) 807 (71.2) ,0.001
Present 66 (76) 16 (27) 4 (50) 326 (28.8) (84.161)
ER
0 13 (15) 7 (12) 0 128 (10.3) Ns
.1% 74 (85) 52 (88) 8 (100) 1005 (88.7)
PR
0 27 (31) 10 (17) 0 194 (17) ,0.001
.1% 60 (69) 49 (83) 8 (100) 939 (83) (10.849)
HER2
Negative 62 (71) 52 (88) 7 (87) 994 (88) ,0.001
Positive 25 (29) 7 (12) 1 (3) 139 (12) (19.049)
Ki67
,14% 20 (23) 24 (40.6) 2 (25) 480 (42.3) ,0.001
$14% 67 (77) 35 (59.3) 6 (85) 653 (57.7) (12.346)
Legend: US/FNA: US-guided FNA; US: Ultrasonography; FNA: Fine-Needle Aspiration cytology; VI: vascular invasion; ER: Estrogen Receptor; PR: Progesterone Receptor.
doi:10.1371/journal.pone.0106640.t005
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tumours. As expected, our results confirmed that malignant
axillary lymph nodes, following US-guided FNA, correlated with
large tumour size (.20 mm) [23,24]; nevertheless, 31% of the
tumours were classified as pT1 (#20 mm), and of these, 3 out of
27 (11.5%) were less than 1 cm. Moreover, in the same subgroup
of pT1 cases with malignant US-guided FNA, 9 patients out to 27
showed 1 to 3 metastatic lymph nodes and the 18 cases had more
than 3 metastatic lymph nodes.
Taking these parameters into account, it is evident that
validating the reliability of the proposed method to identify a
priori (before any type of surgery) the patients at high risk of
axillary metastases is of both clinical and surgical relevance.
Pre-surgical examination of axillary lymph nodes by US itself
has good specificity. In one study, the detection of suspicious
lymph nodes by US was correlated with a high number of
metastatic axillary lymph nodes [11]. However, US alone is
characterised by low sensitivity in defining the presence of
metastases [12,25]. The additional cytological assessment of
axillary lymph nodes using US-guided FNA improves sensitivity
and reaches an absolute specificity of 100% for the diagnosis of
metastases [9,26]. In particular, we showed that while .50% of
patients with a SLN affected by macrometastases did not show
additional metastases in the axilla, none of the patients with a
positive US-guided FNA had negative axillary lymph nodes. In
addition, the US-guided FNA method is able to better identify
breast cancer patients presenting with .3 metastatic lymph nodes
(63% US-guided FNA versus 26.8% of SLN macrometastases and
2.7% of SLN micrometastases) than the SLN method.
Therefore, the take-home message of the present findings,
which confirms the results of van Wely et al. [13], is that positive
US-guided FNA cytology performed on a single lymph node could
be a marker for the possible involvement of .1 axillary lymph
node, particularly in large tumours, and thus reliably leads to one-
step ALND.
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